Hypertension (HTN)NCT07177989
Combined Effects of Alternate Nostril Breathing and Aerobic Interval Training on Blood Pressure and Heart Rate Products in Patients With Hypertension
A study testing Experimental Group and interventional group A in people with Hypertension (HTN), run by Foundation University Islamabad at 1 site in Pakistan.
Trial summary
Hypertension (HTN) is the foremost preventable risk factor for cardiovascular disease (CVD) and all-cause mortality, contributing to over 7 million deaths annually within the nearly 17 million attributed to CVD. Read more about this study
- Who is it for?
- Ages 25 to 50 years
- Conditions the study is for
- Hypertension (HTN)
- What is being tested?
- Experimental Group and interventional group A
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 sitePakistan
- Study dates
- 15 Jan 2025to 15 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 25- 50 years -males and females
- Patients diagnosed with stage 1 hypertension 130 - 139 / 80 - 89 mmHg and stage 2 hypertension, BP level ≥140/90 mmHg. according to AHA/ACC 2017 Guidelines-Individuals who are able to understand and follow the instructions for exercise
Who cannot join
- Diagnosed with any current infections
- subjects with diagnosed musculoskeletal or neurological conditions which hinder participation in physical activity program
- Active Smokers
- Those with any contraindication to exercise testing or training.
- Pregnant females
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Foundation University College of Physical Therapy, Islamabad, 44000
Rawalpindi, 46000
About this study
Hypertension (HTN) is the foremost preventable risk factor for cardiovascular disease (CVD) and all-cause mortality, contributing to over 7 million deaths annually within the nearly 17 million attributed to CVD. Effective management through lifestyle modifications, including aerobic exercises specifically interval training presents a promising avenue for blood pressure regulation by promoting vasodilation and regulating the autonomic nervous system. Likewise, alternate nostril breathing has demonstrated efficacy in lowering blood pressure by optimizing oxygenation and improving endothelial function but their combined effect on BP measures is yet to be determined. Hence this study aims to determine the combined effects of aerobic interval training with and without alternate nostril breathing on blood pressure, rate pressure product and quality of life in patients with hypertension.
- Conditions
- Hypertension (HTN)
- Being tested
- Experimental Group, interventional group A
- Keywords
- hypertension, intensity interval training, nostril breathing, heart rate, blood pressure
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental GroupOther
The interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise heart rate will be calculated using the Karvonen formula for the base line week and the following weeks.Following each aerobic session, they'll practice Alternate Nostril Breathing (ANB), beginning with 5 minutes in the first week and progressing to 10 minutes thereafter. ANB involves specific hand positioning and breathing techniques to promote relaxation and balance. All sessions will be supervised by a physiotherapist.
interventional group AOther
In interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down phase lasting 5-7 minutes, allowing the heart rate to gradually return to baseline and preventing post-exercise hypotension. From the second week onwards, the aerobic training session will begin with a 5-minute warm-up to prepare the body and gradually increase heart rate. The main workout involves a cycle ergometer, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes. The session ends with a 5-7 min
| Study group | Role | What they receive |
|---|---|---|
| Interventional group (Group B) | Experimental | Patients in this group will perform alternative nostril breathing along with aerobic interval training.
A protocol of total 5 weeks. Three sessions per week on alternate days will be done under the supervision of physiotherapist.
All outcome measurements would be performed first at baseline and terminal after the 5 weeks intervention period Receives: Other: Experimental Group |
| Interventional group (Group A) | Active comparator | Patients in tis group will perform aerobic interval training. A protocol of total 5 weeks. Three sessions per week on alternate days will be done under the supervision of physiotherapist.
All outcome measurements would be performed first at baseline and terminal after the 5 weeks intervention period Receives: Other: interventional group A |
What is being measured
The primary outcome is the main question the study is designed to answer.
heart rate
heart rate will be measured by pulse oximeter
Measured: 05 weeks
blood pressure
it will be measured by pulse oximeter
Measured: 05 weeks
Rate pressure product
it will be evaluated by formula : systolic blood pressure x heart rate resting by using sphygmomanometer
Measured: 05 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start15 Jan 2025
- Primary completion15 Jan 2026 (estimated)
- Study completion15 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertension (HTN)Studies of the same condition, open and under way.
- More trials run by Foundation University IslamabadThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a randomized controlled trial having two groups. One group (Group B), will receive alternative nostril breathing along with aerobic interval training and the other group group B) will receive only aerobic interval training.
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Foundation University Islamabad
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177989
- Sponsor's protocol ID
- FUI/CTR/2025/92
- Status last verified
- Sep 2025
- First submitted
- 10 Sep 2025
- Last updated
- 17 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Effects of Alternate Nostril Breathing and Aerobic Interval Training on Blood Pressure and Heart Rate Products in Patients With Hypertension
- ClinicalTrials.gov ID
- NCT07177989
- Acronym / sponsor ID
- FUI/CTR/2025/92
- Conditions
- Hypertension (HTN)
- Keywords
- hypertension, intensity interval training, nostril breathing, heart rate, blood pressure
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Foundation University IslamabadUniversity, hospital or other
- Study start
- 15 Jan 2025 (actual)
- Primary completion
- 15 Jan 2026 (estimated)
- Study completion
- 15 Feb 2026 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypertension (HTN) is the foremost preventable risk factor for cardiovascular disease (CVD) and all-cause mortality, contributing to over 7 million deaths annually within the nearly 17 million attributed to CVD. Effective management through lifestyle modifications, including aerobic exercises specifically interval training presents a promising avenue for blood pressure regulation by promoting vasodilation and regulating the autonomic nervous system. Likewise, alternate nostril breathing has demonstrated efficacy in lowering blood pressure by optimizing oxygenation and improving endothelial function but their combined effect on BP measures is yet to be determined. Hence this study aims to determine the combined effects of aerobic interval training with and without alternate nostril breathing on blood pressure, rate pressure product and quality of life in patients with hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a randomized controlled trial having two groups. One group (Group B), will receive alternative nostril breathing along with aerobic interval training and the other group group B) will receive only aerobic interval training.
| Arm | Type | Receives |
|---|---|---|
| Interventional group (Group B) | Experimental | Other: Experimental GroupPatients in this group will perform alternative nostril breathing along with aerobic interval training. A protocol of total 5 weeks. Three sessions per week on alternate days will be done under the supervision of physiotherapist. All outcome measurements would be performed first at baseline and terminal after the 5 weeks intervention period |
| Interventional group (Group A) | Active comparator | Other: interventional group APatients in tis group will perform aerobic interval training. A protocol of total 5 weeks. Three sessions per week on alternate days will be done under the supervision of physiotherapist. All outcome measurements would be performed first at baseline and terminal after the 5 weeks intervention period |
Who may qualify
- Ages
- 25 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Adults aged 25- 50 years -males and females
- Patients diagnosed with stage 1 hypertension 130 - 139 / 80 - 89 mmHg and stage 2 hypertension, BP level ≥140/90 mmHg. according to AHA/ACC 2017 Guidelines-Individuals who are able to understand and follow the instructions for exercise
Key exclusion criteria (5 listed)
- Diagnosed with any current infections
- subjects with diagnosed musculoskeletal or neurological conditions which hinder participation in physical activity program
- Active Smokers
- Those with any contraindication to exercise testing or training.
- Pregnant females
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental GroupThe interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise heart rate will be calculated using the Karvonen formula for the base line week and the following weeks.Following each aerobic session, they'll practice Alternate Nostril Breathing (ANB), beginning with 5 minutes in the first week and progressing to 10 minutes thereafter. ANB involves specific hand positioning and breathing techniques to promote relaxation and balance. All sessions will be supervised by a physiotherapist. | Other | Interventional group (Group B) |
| interventional group AIn interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down phase lasting 5-7 minutes, allowing the heart rate to gradually return to baseline and preventing post-exercise hypotension. From the second week onwards, the aerobic training session will begin with a 5-minute warm-up to prepare the body and gradually increase heart rate. The main workout involves a cycle ergometer, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes. The session ends with a 5-7 min | Other | Interventional group (Group A) |
Primary outcome
heart rate
Time frame: 05 weeks
heart rate will be measured by pulse oximeter
blood pressure
Time frame: 05 weeks
it will be measured by pulse oximeter
Rate pressure product
Time frame: 05 weeks
it will be evaluated by formula : systolic blood pressure x heart rate resting by using sphygmomanometer
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
Related trials for Hypertension (HTN)
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental Group and interventional group A in people with Hypertension (HTN), run by Foundation University Islamabad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sameen Fatima, DPT (03335169660, sameenfatimaniazi@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
heart rate (time frame: 05 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.